Skip to content
Study details
Enrolling now

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

Yale University
NCT IDNCT03907046ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

700

Study length

about 7.3 years

Ages

18+

Locations

183 sites in AL, AR, AZ +41

What this study is about

This trial is testing whether apixaban, a medication, is better than aspirin at preventing strokes or death in people who have had a brain bleed (ICH) and atrial fibrillation. The goal is to see if apixaban also improves how well patients can function after the stroke.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Apixaban
  • 2.Take Aspirin

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
OralOral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

apixaban (Factor Xa inhibitor; prevents clot formation), acetylsalicylic acid

Drug routes

oral, oral (Delayed Release Oral Tablet)

Body systems

Cardiology / Heart